Awakn Life Sciences Reports Strong Q2 2022 Results
Awakn delivered revenue growth of 34% in Q2 Awakn also announces closing of first tranche of private placement financing TORONTO, CANADA, Sept 15, 2022 – Awakn Life Sciences Corp. (NEO:…
---
News
Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis® Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of its MDMA Program
TORONTO, CANADA, Sept, 12 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…
Awakn Life Sciences Signs Agreement With A Leading Drug Development Company to Deepen IP Moat For Its Lead Program
Agreement Provides 12-Month Exclusive Period to Agree in-Licensing Deal for Proprietary Formulation of Ketamine TORONTO, CANADA, August 25, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating…
Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
Licensing Partnership with Wellbeings® marks entry into Canadian addiction treatment and relapse prevention market TORONTO, CANADA, August 18, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating…
Awakn Life Sciences Expands Commercial Operations Into The U.S. – First Licensing Partnership Agreement With Revitalist 
Awakn enters the U.S. addiction treatment and relapse prevention market TORONTO, CANADA, August 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing,…
Awakn Life Sciences’ Phase III Trial Approved For ~CA$2.5 Million Funding From UK State Covering 66% of Costs
Phase III Trial to Cost ~CA$3.75 million with Awakn’s contribution expected to be ~CA$1.25 million Marks First Psychedelic Phase III Trial Ever to Receive Government Funding TORONTO, CANADA, 20 July,…
Awakn Provides a Business & Corporate Update
TORONTO, CANADA, July 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…
Awakn Receives UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical Development Program – Ketamine-Assisted Therapy For Alcohol Use Disorder
Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III TORONTO, CANADA, July 05, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE:…
Awakn Life Sciences to Present In Upcoming June 2022 Conferences
TORONTO, CANADA, June 20, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term…
Awakn Life Sciences Reports Results for Quarter Ended April 30, 2022
Awakn delivered revenue growth of 24% in the quarter TORONTO, CANADA, June 14, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…
Awakn Life Sciences Appoints Biotech and Investment Veteran Dennis Purcell as a Special Advisor to the CEO
Seasoned Leader Brings Deep Knowledge of US Biotech Market to Awakn TORONTO, CANADA, June 7, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…
Awakn Life Sciences Initiates Follow-on Behavioral Study to Focus on Gambling Disorder
Study Initiated Following Recent Successful Pilot Study and Patent Filing TORONTO, CANADA, June 2, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application For The Treatment Of Behavioral Addictions
Successful Behavioral Addiction Study Supplied Data for Patent TORONTO, CANADA, May 26, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and commercializing…
Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson Of Iter Investments For ‘The Investor Hotseat’ Via Live Stream On May 26th
TORONTO, CANADA, May 24, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus…
Awakn Life Sciences Completes World’s First Ketamine Study For A Range Of Behavioral Addictions
Promising Results Merit Larger Study Which Awakn is Initiating TORONTO, CANADA, May 19, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and…
Awakn Life Sciences Appoints Uk Leader In Addictions Psychiatry, Dr. Arun Dhandayudham, As Chief Medical Officer
Dr. Dhandayudham Brings Significant Frontline Addiction and Mental Health Medical Leadership Experience to Awakn TORONTO, CANADA, May 17, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a…
Awakn Life Sciences Reports Fiscal Fourth Quarter And Fiscal Year January 31, 2022, Results
TORONTO, CANADA, April 28, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction,todayis reporting…
Awakn Provides Shareholders With A Business Update On Its Three Ketamine-Assisted Therapy Clinics In The UK And Norway
TORONTO, CANADA, April 13, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering revolutionary therapeutics to treat addiction, today is providing shareholders with…
Awakn Successfully Completes Phase One Of Its Drug Discovery Program.
Two Chemical Series Identified To Facilitate Lead Optimisation Activities TORONTO, CANADA, April 6, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering…
Awakn Life Sciences to Participate in Upcoming April 2022 Conferences
Toronto, Canada–(Newsfile Corp. – April 5, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat…
Awakn Life Sciences Announces Closing of Private Placement
Toronto, Ontario–(Newsfile Corp. – March 22, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a biotechnology company, researching, developing and delivering psychedelic…
Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
London Clinic Will Begin Delivering Ketamine-Assisted Therapy for Addiction & Mental Health. Third Location Adds to Two Existing Operatons in Bristol and Oslo. Toronto, Ontario–(Newsfile Corp. – March 17, 2022)…
Awakn Life Sciences Appoints Kevin Lorenz as U.S. Head of Commercial Development
Brings Over 20 Years of Commercial Biotech Experience to Lead Awakn’s Therapeutics Commercialization Activities in the U.S. TORONTO, CANADA, MARCH 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE:…
Awakn Life Sciences to Participate at Upcoming March 2022 Conferences
TORONTO, CANADA, March 09, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction, announced today that…
Awakn Files Patent For A New Class Of Entactogen-Like Molecules
Entactogen NCE series enhances the potential to treat a broad range of addictions TORONTO, CANADA, FEBRUARY 17, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company…
Awakn Life Sciences’ Professor Celia Morgan Named One Of The Most Influential Women In The Psychedelics Industry
Professor Morgan, Awakn’s Head of Ketamine-Assisted Therapy for Addiction, named one of the 16 most influential women shaping the future of psychedelics by Insider TORONTO, CANADA, 15 February 2022 – Awakn…
Awakn Life Sciences to Host Fireside Chat with Dr. Ben Sessa, Chief Medical Officer, on March 2nd at 11:00am EST
Dr. Sessa Will Discuss the Promise of Psychedelic Medicine in Treating Addiction Toronto, Ontario–(Newsfile Corp. – February 10, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954)…
Awakn Life Sciences Files Patent Application For A New Class Of Entactogen-Like Molecules To Treat A Broad Range Of Addictions
Novel Entactogen NCE series enhances the potential for improved treatment of addiction TORONTO, CANADA, 26 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching,…
Awakn Life Sciences Signs MOU With MAPS
Agreement to explore a partnership for MDMA-Assisted Therapy for treatment of Alcohol Use Disorder in Europe TORONTO, CANADA, 19 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF)…
Awakn Announces Positive Results From Phase II A/B Clinical Trial
Primary and secondary endpoints achieved, including 86% abstinence over 6 months post treatment and no serious adverse events. TORONTO, CANADA, 11 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:…
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder To Include Additional Behavioral Addictions
Groundbreaking Psychedelic study will investigate Binge Eating Disorder, Compulsive Sexual Behavior, and Internet Gaming Disorder TORONTO, CANADA, 05 January 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE:954) (Awakn), a biotechnology company developing…
Awakn Announces Voluntary Lock-Up Agreement Extension With Management, Board Of Directors And Key Shareholders
Management, the Board of Directors, and key shareholders represent approximately 11.5 million shares or 46.1% of the issued and outstanding shares. TORONTO, CANADA, 04 January 2022 – Awakn Life Sciences Corp….
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results And Business Highlights
TORONTO, CANADA, 15 DECEMBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat…
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors
TORONTO, CANADA, December 14, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the appointment…
Awakn Life Sciences Strengthens Executive Leadership Team
Kate Butler To Be Appointed CFO, Jonathan Held, Current CFO, To Be Appointed Chief Business Officer. TORONTO, CANADA, 30 November 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’…
Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK
With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase III Toronto, Ontario (November 16, 2021) – Awakn Life Sciences Corp….
Awakn Life Sciences Announces The Findings From Phase II A/B Study Are To Be Published In American Journal Of Psychiatry
Worlds’s First Controlled Study To Investigate Ketamine-Assisted Psychotherapy TORONTO, CANADA, November 4, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines…
Awakn Life Sciences to Participate at the Wonderland: Miami Conference in November 2021
Toronto, Ontario–(Newsfile Corp. – November 2, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies)…
Awakn Life Sciences Identifies New Chemical Series Via Its Drug Discovery Program
This Further Defines Development Pathways For Next Generation Of Psychedelic Medicines To Treat Addiction. TORONTO, CANADA, October 28, 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology…
Awakn Life Sciences To Present At The Benzinga Global Small Cap Conference
TORONTO, CANADA, 22 OCTOBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that Chief…
Awakn Life Sciences Bristol Clinic Receives Care Quality Commission Approval To Begin Treatments In The UK’s First Medical Psychedelic Clinic.
The clinic will begin delivering ketamine-assisted psychotherapy treatments in October. TORONTO, CANADA, 20 October 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company…
Awakn Life Sciences Announces Closing Of Acquisition Of Leading Ketamine-Assisted Psychotherapy Clinic In Norway
Transaction concludes with the launch of “Awakn Clinics Oslo AS” as part of Awakn Life Sciences Nordic Expansion TORONTO, October 05, 2021 – Awakn Life Sciences Corp. (“Awakn” or the “Company”),…
Awakn Life Sciences acquires Exclusive Rights To MDMA Research From Imperial College London
This was the world’s first published study assessing MDMA-assisted psychotherapy as a treatment for addiction TORONTO, September 23, 2021 – Awakn Life Sciences Corp. (Awakn), (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) a…
Awakn Life Sciences to Acquire Leading Ketamine-assisted Psychotherapy Clinic in Norway
Launches Nordics Regional Expansion Dr. Lowan Stewart, One of Europe’s Preeminent Ketamine Physicians, Appointed as Awakn’s Regional Director for the Nordics TORONTO, September ##, 2021 – Awakn Life Sciences Corp. (“Awakn”…
Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights
TORONTO, CANADA, 15 SEPTEMBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better…
Awakn Life Sciences announces DTC eligibility
TORONTO, CANADA, 02 SEPTEMBER 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic medicines to treat Addiction, announces that…
Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan
Recruitment Has Commenced for the First-Of-Its-Kind, U.K. – based Study, Led by Renowned Ketamine Researcher Toronto, Ontario–(Newsfile Corp. – August 24, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:…
Awakn Life Sciences Begins Trading on the OTCQB® Venture Market Under the Symbol ‘AWKNF’ on August 12th
Toronto, Ontario–(Newsfile Corp. – August 12, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better…
Awakn Life Sciences to Present at the Canaccord Genuity 41st Annual Virtual Growth Conference
Toronto, Ontario–(Newsfile Corp. – August 9, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to…
Awakn Life Sciences Announces Its Second Location in the UK for “Awakn Clinics London,” Providing Treatment to the Largest City in the UK
The clinic will deliver psychedelic-assisted psychotherapy treatments for Addiction and other mental health conditions and is scheduled to open during the fourth quarter of 2021. Awakn Clinics London will join…
Awakn Life Sciences to Commence Trading on the OTC Market on July 26, 2021 Under the Symbol ‘AWKNF’
Toronto, Ontario–(Newsfile Corp. – July 26, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to…
Awakn Life Sciences Announces The Addition Of Renowned Substance Addiction Researcher Professor Barbara Mason To Its Clinical Advisory Board
TORONTO, CANADA, 22 JULY 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering medicines to better treat Addiction, is delighted to…
Awakn Life Sciences Initiates Research Program To Further Develop Ketamine-assisted Therapies For Treating Addiction
Program to focus on developing and delivering new treatments for substance and behavioral addictions. TORONTO, CANADA, 14 JULY 2021 – Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company…
Awakn Establishes Preclinical And Clinical Expert Advisory Boards To Optimize Delivery Of Its Expanding Development Pipeline
Awkan’s Chief Research Officer Prof David Nutt will chair both advisory boards with Prof Stephen Husbands, Prof Harriet De Wit, and Prof Kevin Fone joining the preclinical advisory board. TORONTO,…
Awakn Life Sciences Files Patent Applications In U.S. For AWKN001 And AWKN002, Two Next- Generation New Chemical Entities [NCEs] To Treat A Broad Range Of Addiction Indications
Broadening of intellectual property portfolio for these two NCEs clearly defines development pathway for the next generation of psychedelic medicines to treat addiction TORONTO, CANADA, 28 June 2021 – Awakn…
Awakn Life Sciences Appoints Addiction Expert Prof. David Nutt As Chief Research Officer
PROF. NUTT WILL DRIVE PROGRESSION OF A PIPELINE OF NEW PSYCHEDELIC MEDICINES, HELPING TO DEFINE A CLEAR DEVELOPMENT PATHWAY TO TREAT ADDICTION THROUGH PSYCHEDELIC MEDICINES TORONTO, CANADA, 24 June 2021…
Awakn Life Sciences Corp. Announces Completion Of Reverse Takeover Transaction, Release From Escrow Of Private Placement Proceeds, And Final Approval For Listing On Neo Exchange
Vancouver, B.C., June 17, 2021 – Further to its press release date May 17, 2021, Awakn Life Sciences Corp. (formerly 1169082 B.C. Ltd.) (the “Company”) is pleased to announce that…
Awakn Life Sciences to participate in the h.C. Wainwright psychedelics in psychiatry and beyond virtual conference
TORONTO, Ontario, June 10, 2021 – Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat Addiction, announced today that Anthony…
Awakn Life Sciences Completes Previously Announced Private Placement For Gross Proceeds Of $8.3 Million
Vancouver, B.C., June 8, 2021 – 1169082 B.C. Ltd. (the “Company”) and Awakn Life Sciences Inc. (“Awakn”), are pleased to announce the closing of the previously announced brokered private placement…
Awakn Life Sciences Inc. and 1169082 B.C. Ltd. Enter into Binding Agreement for Reverse Takeover Transaction
Vancouver, British Columbia–(Newsfile Corp. – May 17, 2021) – 1169082 B.C. Ltd. (the “Company”) is pleased to announce that it has entered into a definitive binding amalgamation agreement dated May 13, 2021…
Awakn Initiates New Chemical Entity Program With Evotec And David Nutt
Defining clear development pathway for next generation of psychedelic medicines to treat addiction Awakn announces today the initiation of a new chemical entity (NCE) development program to strengthen Awakn’s pipeline…
Awakn Announces Two Key Appointments to Its Board of Directors
Awakn announces the appointment of Stephen Page and Professor John Papastergiou as independent non-executive directors to the company’s Board of Directors. Adding significant pharmaceutical and healthcare sector experience and independent…
Awakn Launches Digital Unit and Signs Agreement with the University of Exeter
First project to use advanced analytics to explore identity shifts in alcohol addiction Awakn launches ‘Awakn Digital’, a new unit focused on using advanced analytics to improve the effectiveness of…
Psychedelic Molecule Development Data Acquired by Awakn from Prof. David Nutt
Prof. Nutt appointed Head of Research to Lead Awakn’s Next-Gen Psychedelic Molecule Development Awakn Life Sciences announces the acquisition of significant proprietary research data on next generation candidate MDMA and…
Sign Up for Newsletter
MAIN OFFICE
18 Dukes Road,
London WC1H 9PY, United Kingdom
UK OFFICE
1 Regent Street, Bristol, BS8 4HW, United Kingdom
© 2021 Awakn Life Sciences Corp | Privacy Policy | Appropriate Use Policy
